Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Host genetic determinants in hepatitis C virus infection

Genes & Immunity volume 5, pages 237–245 (2004)Cite this article

Abstract

In addition to viral and environmental/behavioural factors, host genetic diversity is believed to contribute to the spectrum of clinical outcomes in hepatitis C virus (HCV) infection. This paper reviews the literature with respect to studies of host genetic determinants of HCV outcome and attempts to highlight trends and synthesise findings. With respect to the susceptibility to HCV infection, several studies have replicated associations of the HLA class II alleles DQB1*0301 and DRB1*11 with self-limiting infection predominantly in Caucasian populations. Meta-analyses yielded summary estimates of 3.0 (95% CI: 1.8–4.8) and 2.5 (95% CI: 1.7–3.7) for the effects of DQB1*0301 and DRB1*11 on self-limiting HCV, respectively. Studies of genetics and the response to interferon-based therapies have largely concerned single-nucleotide polymorphisms and have been inconsistent. Regarding studies of genetics and the progression of HCV-related disease, there is a trend with DRB1*11 alleles and less severe disease. Studies of extrahepatic manifestations of chronic HCV have shown an association between DQB1*11 and DR3 with the formation of cryoglobulins. Some important initial observations have been made with respect to genetic determinants of HCV outcome. Replication studies are needed for many of these associations, as well as biological data on the function of many of these polymorphisms.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Seeff LB . Natural history of chronic hepatitis C. Hepatology 2002; 36: S35–S46.

    PubMed  Google Scholar 

  2. Rodger AJ, Roberts S, Lanigan A et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582–587.

    Article  CAS  PubMed  Google Scholar 

  3. Alter HJ, Conry-Cantilena C, Melpolder J et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26: 29S–33S.

    Article  CAS  PubMed  Google Scholar 

  4. Alter M, Gerety R, Smallwood L et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982; 145: 886–893.

    Article  CAS  PubMed  Google Scholar 

  5. Tong M, El-Farra N, Reikes A et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463–1466.

    Article  CAS  PubMed  Google Scholar 

  6. Hoofnagle JH . Course and outcome of hepatitis C. Hepatology 2002; 36: S21–S29.

    PubMed  Google Scholar 

  7. Lovy MR, Starkebaum G . Rheumatic disorders associated with hepatitis C. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 535–557.

    Article  CAS  PubMed  Google Scholar 

  8. Mehta SH, Strathdee SA, Thomas DL . Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev 2001; 23: 302–312.

    Article  CAS  PubMed  Google Scholar 

  9. Martinelli AL, Zago MA, Roselino AM et al. Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatitis C virus infection. Am J Gastroenterol 2000; 95: 3516–3521.

    Article  CAS  PubMed  Google Scholar 

  10. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27: 1661–1669.

    Article  CAS  PubMed  Google Scholar 

  11. Manns MP, Rambusch EG . Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31 (Suppl 1): 39–42.

    Article  PubMed  Google Scholar 

  12. Yee LJ, Kelleher PK, Goldin RD et al. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepatitis (in press).

  13. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

    Article  CAS  PubMed  Google Scholar 

  14. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.

    Article  CAS  PubMed  Google Scholar 

  15. Lin TM, Chen CJ, Wu MM et al. Hepatitis B virus markers in Chinese twins. Anticancer Res 1989; 9: 737–741.

    CAS  PubMed  Google Scholar 

  16. Alric L, Fort M, Izopet J et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology 1997; 113: 1675–1681.

    Article  CAS  PubMed  Google Scholar 

  17. Alric L, Fort M, Izopet J et al. Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens 2000; 56: 154–158.

    Article  CAS  PubMed  Google Scholar 

  18. Asti M, Martinetti M, Zavaglia C et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology 1999; 29: 1272–1279.

    Article  CAS  PubMed  Google Scholar 

  19. Barrett S, Ryan E, Crowe J . Association of the HLA-DRB1*01 allele with spontaneous viral clearance in an Irish cohort infected with hepatitis C virus via contaminated anti-D immunoglobulin. J Hepatol 1999; 30: 979–983.

    Article  CAS  PubMed  Google Scholar 

  20. Bosi I, Ancora G, Mantovani W et al. HLA DR13 and HCV vertical infection. Pediatr Res 2002; 51: 746–749.

    Article  PubMed  Google Scholar 

  21. Caocci G, Demelia L, Coppola RC et al. Human leucockyte antigen molecules and susceptibility to hepatitis C virus infection in Sardinian patients. Eur J Intern Med 1998; 9: 281–285.

    Google Scholar 

  22. Chen DF, Endres W, Kliem V et al. No significant influence of HLA determinants on susceptibility to hepatitis C virus infection in Caucasian patients with end-stage renal disease. Liver 1996; 16: 384–389.

    Article  CAS  PubMed  Google Scholar 

  23. Congia A, Clemente M, Dessi C et al. HLA class II genes in chronic hepatitis C virus infection and associated immunological disorders. Hepatology 1996; 24: 1338–1341.

    Article  CAS  PubMed  Google Scholar 

  24. Constantini PK, Wawrzynowicz-Syczewska M, Clare M et al. Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 2002; 22: 404–412.

    Article  CAS  PubMed  Google Scholar 

  25. Cramp ME, Carucci P, Underhill J et al. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998; 29: 207–213.

    Article  CAS  PubMed  Google Scholar 

  26. Fanning LJ, Levis J, Kenny-Walsh E et al. Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. Hepatology 2000; 31: 1334–1337.

    Article  CAS  PubMed  Google Scholar 

  27. Hennig BJ, Hellier S, Frodsham AJ et al. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002; 3: 359–367.

    Article  CAS  PubMed  Google Scholar 

  28. Hohler T, Gerken G, Notghi A et al. MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 1997; 27: 259–264.

    Article  CAS  PubMed  Google Scholar 

  29. Kuzushita N, Hayashi N, Moribe T et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998; 27: 240–244.

    Article  CAS  PubMed  Google Scholar 

  30. Lechmann M, Schneider EM, Giers G et al. Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest 1999; 29: 337–343.

    Article  CAS  PubMed  Google Scholar 

  31. Louagie HK, Brouwer JT, Delanghe JR et al. Haptoglobin polymorphism and chronic hepatitis C. J Hepatol 1996; 25: 10–14.

    Article  CAS  PubMed  Google Scholar 

  32. Mangia A, Gentile R, Cascavilla I et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 1999; 30: 984–989.

    Article  CAS  PubMed  Google Scholar 

  33. Martinetti M, Pacati I, Daielli C et al. Critical role of Val/Gly86 HLA-DRB dimorphism in the neonatal resistance or susceptibility to maternal hepatitis C virus infection. Pediatr Infect Dis J 1997; 16: 1001–1002.

    Article  CAS  PubMed  Google Scholar 

  34. McKiernan SM, Hagan R, Curry M et al. The MHC is a major determinant of viral status, but not fibrotic stage, in individuals infected with hepatitis C. Gastroenterology 2000; 118: 1124–1130.

    Article  CAS  PubMed  Google Scholar 

  35. Minton EJ, Smillie D, Neal KR et al. Association between MHC class II alleles and clearance of circulating hepatitis C virus. J Infect Dis 1998; 178: 39–44.

    Article  CAS  PubMed  Google Scholar 

  36. Okada F, Shiraki T, Maekawa M, Sato S . A p53 polymorphism associated with increased risk of hepatitis C virus infection. Cancer Lett 2001; 172: 137–142.

    Article  CAS  PubMed  Google Scholar 

  37. Promrat K, McDermott DH, Gonzalez CM et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124: 352–360.

    Article  CAS  PubMed  Google Scholar 

  38. Promrat K, McDermott DH, Gonzalez CM et al. Correction: association of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003; 124: 1168.

    Article  CAS  Google Scholar 

  39. Thursz M, Yallop R, Goldin R et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999; 354: 2119–2124.

    Article  CAS  PubMed  Google Scholar 

  40. Tibbs C, Donaldson P, Underhill J et al. Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in Northern European Caucasoids. Hepatology 1996; 24: 1342–1345.

    Article  CAS  PubMed  Google Scholar 

  41. Thio CL, Thomas DL, Goedert JJ et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001; 184: 16–21.

    Article  CAS  PubMed  Google Scholar 

  42. Thio CL, Gao X, Goedert JJ et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76: 4792–4797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Van Vlierberghe H, Delanghe JR, De Bie S et al. Association between Cys282Tyr missense mutation and haptoglobin phenotype polymorphism in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2001; 13: 1077–1081.

    Article  CAS  PubMed  Google Scholar 

  44. Vejbaesya S, Songsivilai S, Tanwandee T et al. HLA association with hepatitis C virus infection. Hum Immunol 2000; 61: 348–353.

    Article  CAS  PubMed  Google Scholar 

  45. Verdon R, Pol S, Landais P et al. Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialyzed patients. J Hepatol 1994; 21: 388–393.

    Article  CAS  PubMed  Google Scholar 

  46. Vidigal PG, Germer JJ, Zein NN . Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factor-beta1 genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol 2002; 36: 271–277.

    Article  CAS  PubMed  Google Scholar 

  47. Vitte RL, Fortier C, Richardet JP et al. HLA antigens in patients with chronic hepatitis C. Tissue Antigens 1995; 45: 356–361.

    Article  CAS  PubMed  Google Scholar 

  48. Wawrzynowicz-Syczewska M, Underhill JA, Clare MA et al. HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland. Liver 2000; 20: 234–239.

    Article  CAS  PubMed  Google Scholar 

  49. Woitas RP, Ahlenstiel G, Iwan A et al. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology 2002; 122: 1721–1728.

    Article  CAS  PubMed  Google Scholar 

  50. Yenigun A, Durupinar B . Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J Virol 2002; 76: 1787–1789.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Zavaglia C, Bortolon C, Ferrioli G et al. HLA typing in chronic type B, D and C hepatitis. J Hepatol 1996; 24: 658–665.

    Article  CAS  PubMed  Google Scholar 

  52. Zavaglia C, Martinetti M, Silini E et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998; 28: 1–7.

    Article  CAS  PubMed  Google Scholar 

  53. Yee L, Thursz M . Genetic diversity in the major histocompatability complex and the immune response to infectious diseases. In: Bellamy R (ed) Susceptibility to Infectious Diseases. Cambridge University Press: Cambridge, 2003, pp 77–116.

    Chapter  Google Scholar 

  54. Thursz M . MHC and the viral hepatitides. Q J Med 2001; 94: 287–291.

    Article  CAS  Google Scholar 

  55. Sterne J, Bradburn M, Egger M . Meta-analysis in STATA. In: Egger M, Davey Smith G, Altman D (eds) Systematic Reviews in Health Care: Meta-Anlysis in Context, 2nd edn. BMJ Publishing Group: London, 2001, pp 347–369.

    Chapter  Google Scholar 

  56. Kenny-Walsh E . Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228–1233.

    CAS  PubMed  Google Scholar 

  57. Mangia A, Santoro R, D'Agruma L, Andriulli A . HCV chronic infection and CCR5-Delta 32/Delta 32. Gastroenterology 2003; 124: 868–869.

    Article  PubMed  Google Scholar 

  58. Zhang M, Goedert JJ, O'Brien TR . High frequency of CCR5-Delta 32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1. Gastroenterology 2003; 124: 867–869.

    Article  PubMed  CAS  Google Scholar 

  59. Klein R . Discussion on frequency of the HIV-protective CC chemokine receptor 5-delta32/delta 32 genotype is increased in hepatitis C. Gastroenterology 2003; 124: 1558.

    Article  PubMed  Google Scholar 

  60. Poljak M, Seme K, Marin I et al. Frequency of the 32-base pair deletion in the chemokine receptor CCR5 gene is not increase in hepatitis C patients. Gastroenterology 2003; 124: 1558–1560.

    Article  PubMed  Google Scholar 

  61. Vidigal P, Germer JJ, Zein NN . Clinical significance of IL-10 and TNF-A promoter polymorphisms in chronic hepatitis C (HCV) infection. Gastroenterology 2000; 118: 941A.

    Article  Google Scholar 

  62. Hohler T, Reuss E, Evers N et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002; 360: 991–995.

    Article  PubMed  Google Scholar 

  63. Alric L, Izopet J, Fort M et al. Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum Immunol 1999; 60: 516–523.

    Article  CAS  PubMed  Google Scholar 

  64. Almarri A, El Dwick N, Al Kabi S et al. Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome. Hum Immunol 1998; 59: 239–242.

    Article  CAS  PubMed  Google Scholar 

  65. Dincer D, Besisik F, Oguz F et al. Genes of major histocompatibility complex class II influence chronic C hepatitis treatment with interferon in hemodialysis patients. Int J Artif Organs 2001; 24: 212–214.

    Article  CAS  PubMed  Google Scholar 

  66. Dorak MT, Folayan GO, Niwas S et al. C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection. Immunol Res 2002; 26: 167–175.

    Article  CAS  PubMed  Google Scholar 

  67. Edwards-Smith C, Jonsson JR, Purdie D et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alpha. Hepatology 1999; 30: 526–530.

    Article  CAS  PubMed  Google Scholar 

  68. Haruna Y, Miyamoto T, Yasunami R et al. Human leukocyte antigen DRB1 1302 protects against bile duct damage and portal lymphocyte infiltration in patients with chronic hepatitis C. J Hepatol 2000; 32: 837–842.

    Article  CAS  PubMed  Google Scholar 

  69. Coelho-Borges S, Cheinquer H, Cheinquer N et al. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload. Am J Gastroenterol 2002; 97: 1570–1572.

    Article  PubMed  Google Scholar 

  70. Fanning LJ, Levis J, Kenny-Walsh E et al. HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology 2001; 33: 224–230.

    Article  CAS  PubMed  Google Scholar 

  71. Hijikata M, Ohta Y, Mishiro S . Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt −88) correlated with the response of hepatitis C patients to interferon. Intervirology 2000; 43: 124–127.

    Article  CAS  PubMed  Google Scholar 

  72. Hijikata M, Mishiro S, Miyamoto C et al. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (−123 and −88) in vivo and in vitro. Intervirology 2001; 44: 379–382.

    Article  CAS  PubMed  Google Scholar 

  73. Kikuchi I, Ueda A, Mihara K et al. The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998; 10: 859–863.

    Article  CAS  PubMed  Google Scholar 

  74. Matsushita M, Hijikata M, Ohta Y et al. Hepatitis C virus infection and mutations of mannose-binding lectin gene MBL. Arch Virol 1998; 143: 645–651.

    Article  CAS  PubMed  Google Scholar 

  75. Matsushita M, Hijikata M, Ohta Y, Mishiro S . Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol 1998; 29: 695–700.

    Article  CAS  PubMed  Google Scholar 

  76. Matsuyama N, Mishiro S, Sugimoto M et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003; 25: 221–225.

    Article  CAS  PubMed  Google Scholar 

  77. Miyaguchi S, Saito H, Ebinuma H et al. Possible association between HLA antigens and the response to interferon in Japanese patients with chronic hepatitis C. Tissue Antigens 1997; 49: 605–611.

    Article  CAS  PubMed  Google Scholar 

  78. Nishiguchi S, Kaneshiro S, Tanaka M et al. Association of HLA Alleles with Response (especially biochemical response) to interferon therapy in japanese patients with chronic hepatitis C. J Interf Cytok Res 2003; 23: 135–141.

    Article  CAS  Google Scholar 

  79. Par A, Paal M, Horanyi M et al. Role of viral and host factors in the pathogenesis of hepatitis C virus infection and in the response to interferon treatment. Period Biologorum 1998; 100: 515–519.

    Google Scholar 

  80. Pirisi M, Scott CA, Avellini C et al. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol 2000; 113: 546–554.

    Article  CAS  PubMed  Google Scholar 

  81. Rosen HR, McHutchison JG, Conrad AJ et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 714–720.

    Article  CAS  PubMed  Google Scholar 

  82. Sim H, Wojcik J, Margulies M et al. Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C. J Viral Hepatitis 1998; 5: 249–253.

    Article  CAS  Google Scholar 

  83. Sugimoto Y, Kuzushita N, Takehara T et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J Viral Hepatitis 2002; 9: 377–384.

    Article  CAS  Google Scholar 

  84. Yee LJ, Tang J, Gibson AW et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33: 708–712.

    Article  CAS  PubMed  Google Scholar 

  85. Yee LJ, Perez KA, Tang J et al. Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 2003; 187: 1264–1271.

    Article  CAS  PubMed  Google Scholar 

  86. Reuss E, Fimmers R, Kruger A et al. Differential regulation of interleukin-10 production by genetic and environmental factors—a twin study. Genes Immun 2002; 3: 407–413.

    Article  CAS  PubMed  Google Scholar 

  87. Abbas Z, Moatter T . Interleukin (IL) 1beta and IL-10 gene polymorphism in chronic hepatitis C patients with normal or elevated alanine aminotransferase levels. J Pak Med Assoc 2003; 53: 59–62.

    CAS  PubMed  Google Scholar 

  88. Aikawa T, Kojima M, Onishi H et al. HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J Med Virol 1996; 49: 274–278.

    Article  CAS  PubMed  Google Scholar 

  89. Akuta N, Chayama K, Suzuki F et al. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 Allele. J Med Virol 2001; 64: 109–116.

    Article  CAS  PubMed  Google Scholar 

  90. Brandhagen DJ, Gross JB, Poterucha JJ et al. Human leukocyte antigen DR markers as predictors of progression to liver transplantation in patients with chronic hepatitis C. Am J Gastroenterol 2000; 95: 2056–2060.

    Article  CAS  PubMed  Google Scholar 

  91. Czaja AJ, Carpenter H, Santrach PJ et al. DR human leukocyte antigens and disease severity in chronic hepatitis C. J Hepatol 1996; 24: 666–673.

    Article  CAS  PubMed  Google Scholar 

  92. Erhardt A, Maschner-Olberg A, Mellenthin C et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003; 38: 335–342.

    Article  CAS  PubMed  Google Scholar 

  93. Hézode C, Cazeneuve C, Cou O et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999; 31: 979–984.

    Article  PubMed  Google Scholar 

  94. Hue S, Cacoub P, Renou C et al. Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J Infect Dis 2002; 186: 106–109.

    Article  PubMed  Google Scholar 

  95. Higashi Y, Kamikawaji N, Suko H et al. Analysis of HLA alleles in Japanese patients with cirrhosis due to chronic hepatitis C. J Gastroenterol Hepatol 1996; 11: 241–246.

    Article  CAS  PubMed  Google Scholar 

  96. Hohler T, Kruger A, Gerken G et al. Tumor necrosis factor alpha promoter polymorphism at position –238 is associated with chronic active hepatitis C infection. J Med Virol 1998; 54: 173–177.

    Article  CAS  PubMed  Google Scholar 

  97. Knoll A, Kreuzpaintner B, Kreuzpaintner E et al. Hemochromatosis mutation in hepatitis C: histopathology. Gastroenterology 1998; 115: 1307–1309.

    Article  CAS  PubMed  Google Scholar 

  98. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999; 116: 127–134.

    Article  CAS  PubMed  Google Scholar 

  99. Kuzushita N, Hayashi N, Katayama K et al. Increased frequency of HLA DR13 in hepatitis C virus carriers with persistently normal ALT levels. J Med Virol 1996; 48: 1–7.

    Article  CAS  PubMed  Google Scholar 

  100. Kuzushita N, Hayashi N, Kanto T et al. Involvement of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in hepatitis C virus infection. Gastroenterology 1999; 116: 1149–1154.

    Article  CAS  PubMed  Google Scholar 

  101. Martinelli AL, Franco RF, Villanova MG et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol 2000; 102: 152–156.

    Article  CAS  PubMed  Google Scholar 

  102. Negro F, Samii K, Rubbia-Brandt L et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 2000; 60: 21–27.

    Article  CAS  PubMed  Google Scholar 

  103. Peano G, Menardi G, Ponzetto A et al. HLA-DR5 antigen: a genetic factor influencing the outcome of hepatitis C virus infection? Arch Intern Med 1994; 154: 2733–2736.

    Article  CAS  PubMed  Google Scholar 

  104. Pellegris G, Ravagnani F, Notti P et al. B and C hepatitis viruses, HLA-DQ1 and −DR3 alleles and autoimmunity in patients with hepatocellular carcinoma. J Hepatol 2002; 36: 521–526.

    Article  CAS  PubMed  Google Scholar 

  105. Powell EE, Edwards-Smith CJ, Hay JL et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828–833.

    Article  CAS  PubMed  Google Scholar 

  106. Renou C, Halfon P, Pol S et al. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002; 51: 585–590.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Reynolds WF, Patel K, Pianko S et al. A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection. Genes Immun 2002; 3: 345–349.

    Article  CAS  PubMed  Google Scholar 

  108. Silvestri L, Sonzogni L, De Silvestri A et al. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer 2003; 104: 310–317.

    Article  CAS  PubMed  Google Scholar 

  109. Smith BC, Gorve J, Guzail MA et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998; 27: 1695–1699.

    Article  CAS  PubMed  Google Scholar 

  110. Sonzogni L, Silvestri L, De Silvestri A et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 2002; 36: 195–201.

    Article  CAS  PubMed  Google Scholar 

  111. Thorburn D, Curry G, Spooner R et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50: 248–252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Tillmann HL, Chen DF, Trautwein C et al. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001; 48: 714–718.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Wang Y, Kato N, Hoshida Y et al. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 2003; 37: 65–71.

    Article  CAS  PubMed  Google Scholar 

  114. Wozniak MA, Itzhaki RF, Faragher EB et al. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002; 36: 456–463.

    Article  CAS  PubMed  Google Scholar 

  115. Yasunami R, Miyamoto T, Kanda T . HLA-DRB1 is related to the pathological changes of the liver in chronic hepatitis C. Hepatol Res 1997; 7: 3–12.

    Article  Google Scholar 

  116. Yee LJ, Tang J, Herrera J et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000; 1: 386–390.

    Article  CAS  PubMed  Google Scholar 

  117. Tokushige K, Tsuchiya N, Hasegawa K et al. Influence of TNF gene polymorphism and HLA-DRB1 haplotype in Japanese patients with chronic liver disease caused by HCV. Am J Gastroenterol 2003; 98: 160–166.

    Article  CAS  PubMed  Google Scholar 

  118. Hanson EH, Imperatore G, Burke W . HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154: 193–206.

    CAS  PubMed  Google Scholar 

  119. Pietrangelo A . Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003; 124: 1509–1523.

    Article  CAS  PubMed  Google Scholar 

  120. Saadeh S, Cammell G, Carey WD et al. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196–200.

    Article  CAS  PubMed  Google Scholar 

  121. Bataller R, North KE, Brenner DA . Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37: 493–503.

    Article  CAS  PubMed  Google Scholar 

  122. Amoroso A, Berrino M, Canale L et al. Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglbulinemia type II after hepatitis C virus infection? J Hepatol 1998; 29: 36–44.

    Article  CAS  PubMed  Google Scholar 

  123. Cacoub P, Renou C, Kerr G et al. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 2001; 44: 2118–2124.

    Article  CAS  PubMed  Google Scholar 

  124. Czaja A, Carpenter, Herschel A et al. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 1996; 24: 52–59.

    Article  CAS  PubMed  Google Scholar 

  125. Hezode C, Cazeneuve C, Coue O et al. Hemochromatosis Cys282Tyr mutation and liver iron overload in patients with chronic active hepatitis C. Hepatology 1998; 27: 306.

    Article  CAS  PubMed  Google Scholar 

  126. Hijikata M, Miyakawa H, Matsushita M et al. CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C. Biochem Biophys Res Commun 2000; 270: 922–926.

    Article  CAS  PubMed  Google Scholar 

  127. Hwang SJ, Chu CW, Huang DF et al. Genetic predispositions for the presence of cryoglobulinemia and serum autoantibodies in Chinese patients with chronic hepatitis C. Tissue Antigens 2002; 59: 31–37.

    Article  CAS  PubMed  Google Scholar 

  128. Jurado A, Cardaba B, Jara P et al. Autoimmune hepatitis type 2 and hepatitis C virus infection: study of HLA antigens. J Hepatol 1997; 26: 983–991.

    Article  CAS  PubMed  Google Scholar 

  129. Kakizaki S, Takagi H, Murakami M et al. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol 1999; 30: 794–800.

    Article  CAS  PubMed  Google Scholar 

  130. Kakizaki S, Takagi H, Murakami M et al. HA-A2 subtype in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver 2000; 20: 423–424.

    Article  CAS  PubMed  Google Scholar 

  131. Lal P, Fernandes H, Koneru B et al. C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis. Arch Pathol Lab Med 2000; 124: 1632–1635.

    Article  CAS  PubMed  Google Scholar 

  132. Lenzi M, Frisoni M, Mantovani V et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998; 91: 2062–2066.

    Article  CAS  PubMed  Google Scholar 

  133. Gran JT, Husby G, Thorsby E . The association between rheumatoid arthritis and the HLA antigen DR4. Ann Rheum Dis 1983; 42: 292–296.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Manabe K, Donaldson PT, Underhill JA et al. Human leukocyte antigen A1-B8-DR3-DQ2-DPB1*0401 extended haplotype in autoimmune hepatitis. Hepatology 1993; 18: 1334–1337.

    Article  CAS  PubMed  Google Scholar 

  135. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB . Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816–822.

    Article  CAS  PubMed  Google Scholar 

  136. Czaja AJ, Donaldson PT . Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174: 250–259.

    Article  CAS  PubMed  Google Scholar 

  137. Roudier J . Association of MHC and rheumatoid arthritis. Association of RA with HLA-DR4: the role of repertoire selection. Arthritis Res 2000; 2: 217–220.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Korth MJ, Katze MG . Unlocking the mysteries of virus–host interactions: does functional genomics hold the key? Ann N Y Acad Sci 2002; 975: 160–168.

    Article  CAS  PubMed  Google Scholar 

  139. Smith MW, Yue ZN, Korth MJ et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 2003; 38: 1458–1467.

    Article  CAS  PubMed  Google Scholar 

  140. Sarmiento OL, Ford CL, Newbern EC et al. The importance of assessing effect modification when asserting racial differences in associations between human leukocyte antigen class II alleles and hepatitis C virus outcomes. J Infect Dis 2002; 185: 266–268.

    Article  PubMed  Google Scholar 

  141. Hoggart CJ, Parra EJ, Shriver MD et al. Control of confounding of genetic associations in stratified populations: epidemiological methods for studying genes and environmental factors in complex diseases. Am J Hum Genet 2003; 72: 1492–1504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. McKeigue PM . Mapping genes that underlie ethnic differences in disease risk: methods for detecting linkage in admixed populations, by conditioning on parental admixture. Am J Hum Genet 1998; 63: 241–251.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Rothman KJ, Greenland S . Modern Epidemiology. Lippincott-Raven Publishers: Philadelphia, 1998.

    Google Scholar 

  144. Clayton D, McKeigue PM . Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001; 358: 1356–1360.

    Article  CAS  PubMed  Google Scholar 

  145. Constans E . Making medicine personal. Scientist 2002; 16: 44–46.

    Google Scholar 

Download references

Acknowledgements

I thank Drs Mark Thursz, Andy Hall and Chris Wallace for their helpful suggestions and comments on this paper. I thank Dr Sara Thomas for advice regarding systematic review methodology and meta-analyses. I also thank three anonymous reviewers for their helpful suggestions.

Author information

Authors and Affiliations

  1. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA

    L J Yee

Authors
  1. L J Yee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L J Yee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yee, L. Host genetic determinants in hepatitis C virus infection. Genes Immun 5, 237–245 (2004). https://doi.org/10.1038/sj.gene.6364090

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gene.6364090

This article is cited by

Search

Advanced search

Quick links